Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How much will Herceptin really cost?

Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245

8. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245

9. Patients' views of explicit rationing: what are the implications for health service decision-making?

Authors: Nancy Devlin; John Appleby; David Parkin
Journal: J Health Serv Res Policy Date: 2003-07

10. Health care priority setting: principles, practice and challenges.

Authors: Craig Mitton; Cam Donaldson
Journal: Cost Eff Resour Alloc Date: 2004-04-22

36 in total

1. "No respecter of youth": over-representation of young women in Australian television coverage of breast cancer.

Authors: Ross MacKenzie; Simon Chapman; Simon Holding; Annie Stiven
Journal: J Cancer Educ Date: 2010-12 Impact factor: 2.037

2. How much will Herceptin really cost? Balancing local and national priorities is not new.

Authors: Andrew Dillon; Peter Littlejohns
Journal: BMJ Date: 2006-12-09

3. How much will Herceptin really cost? The money is already there.

Authors: Rubin Minhas
Journal: BMJ Date: 2006-12-09

4. Putting the public at the heart of the NHS.

Authors: Will Hutton
Journal: BMJ Date: 2007-01-13

5. NICE appraisals should be everybody's business.

Authors: Jane Wells; Claire Cheong-Leen
Journal: BMJ Date: 2007-05-05

Review 6. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Authors: Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

How much will Herceptin really cost?

1. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.

2. National Institute for Clinical Excellence and its value judgments.

3. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.

4. Herceptin and early breast cancer: a moment for caution.

5. Adjuvant trastuzumab for breast cancer.

6. Patient is to appeal High Court ruling on breast cancer drug.

7. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

8. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

9. Patients' views of explicit rationing: what are the implications for health service decision-making?

10. Health care priority setting: principles, practice and challenges.

1. "No respecter of youth": over-representation of young women in Australian television coverage of breast cancer.

2. How much will Herceptin really cost? Balancing local and national priorities is not new.

3. How much will Herceptin really cost? The money is already there.

4. Putting the public at the heart of the NHS.

5. NICE appraisals should be everybody's business.

Review 6. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Review 7. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?

Review 8. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

9. Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected.

10. Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage.